Member Info for busicat

Initial £300k order from a partner related to the latter's contract with a European Ministry of Defence (MOD) organisation. Further orders are expected over the period of the partner's two-year framework contract.

>10% up: Q1 updates usually land this week of the year it seems, generally followed by a lift in SP for a while. Looks like buys have started early this year.

Well, that seemed quick!

Aviva today announces that, it has completed the acquisition of AIG Life Ltd from Corebridge Financial (a subsidiary of American International Group), for £453m.

The acquisition was cleared by the CMA on 28 March, just before Easter.

But then, it had been first announced on 25 September 2023 (6.5 months ago), whereas the intended acquisition of Friends Life was announced 21 Nov 2014 and completed 13 April 2015 (under 5 months).

Results due out today, but no sign yet.

Investor presentation at 3:00

No quote available on AJBell

Great presentation of the business well on track to achieve what it plans. (RNS says where you can find it)

Slide 22 confirms the Q4 turn to profitability, graphing the nice trend from Adj. EBITDA margin of minus 98% in Q1 to plus 11% in Q4.

I'm thinking this a good one to stick with for future years, especially now they have their foot in the US, where just looking at how LGEN's platform -driven protection business has taken off, it seems the right proposition in PBEE's context could be massive.

Ahead of results today, when extent of turn to profit can be expected to be confirmed, there seems to be surprisingly little interest here.

Record year in 2023 and forecast to be beaten in 2024.

"we are forecasting that 2024 underlying operating profit will be at least double the 2021 level of £211m."

They say this means doubling profit in 3 years instead of the intended 5.

How often do you see that?

Oops! 470p exceeded already : )

Nice start to the day, comparing to LGEN, which fell but ended up recovering. I may have been too cautious with my 466p-470p range for today here

After ad good year for Protection (don't know about other markets) for Aviva, and seeing how L&G have done, my target price for tomorrow is 466p to 470p and div s/be 22.3p if aligned with H1 guidance, I think:

"We expect full year 2023 Group operating profit‡,1 to grow between 5% to 7% from £1,350m in 2022.

We are on track to exceed our Solvency II operating own funds generation‡ target of £1.5bn per annum by 2024 and our cash remittance‡ target of >£5.4bn cumulative (2022-24). We expect to deliver our target of £750m gross cost reduction by 2024 one year early.

We remain committed to delivering for our shareholders. Consistent with previous guidance, we expect to pay a dividend of c.£915m or c.33.4p for 2023, with low-to-mid single digit growth in the cash cost of the dividend thereafter."

..and again today : )

21.8% ROE highest in 7 yrs and record profit before tax of $625.9 million (2022: $275.6 million), along with great growth prospects, are my favourite bits.

Now we know why the Chair invested big here.

19% up explained by US news:

"United States Government has approved adding the company's Food and Drug Administration ("FDA") de Novo Marketing authorized test, kidneyintelX.dkd, to its 10-year Governmentwide Acquisition Contract (GWAC) for early-stage kidney disease bioprognostic? testing services. Pricing for kidneyintelX.dkd is set at $950 per reportable result. The contract, effective through 2031 and offered through the General Services Administration (GSA), covers laboratory testing services provided by any government healthcare facility, including the U.S. Veterans Administration (VA), Department of Defense (DoD) military branches (the Army, Marine Corps, Navy, Air Force, Space Force, and Coast Guard), and Indian Health Services (IHS).

In addition, today National Government Services ("NGS"), a Medicare Administrative Contractor (MAC), is holding its first quarter Open Public Meeting that includes consideration of its proposed coverage policy for KidneyIntelX and kidneyintelX.dkd testing. As disclosed previously, NGS has adopted a consistent payment approach for KidneyIntelX testing that is expected to continue through the finalization of the proposed coverage policy."

2pm is CEO and CFO online presentation relating to the trading update.

I'll be keen to see what impression that makes on any who are able to attend and feedback.

Looks like it!

Congrats ria - probably got the best out of today. Nasdaq now$1.14 - you can see pretty much live at market watch . com no spaces

Sadly still needed to go further so still hanging on!

Up 300% over there at $1.10 vs~$0.27 last week ...and now back up again to $1.22. now I'm wishing I'd followed the US on Friday! Oh well, sitting tight either way

Up 217% and I'm suspecting computer glitch